Some of the major updates include the approval of acalabrutinib (Calquence) for first-line treatment of mantle cell lymphoma, the FDA’s priority review of fam-trastuzumab deruxtecan-nxki (T-DXd; ...

Over the summer, the researchers published a new study in the journal Nutrients showing that Manuka honey could have the ...

DNA catapults into spotlight. A trio of research papers from Stanford Medicine researchers and their international ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

Altamonte Springs, Fla.-based AdventHealth has launched a pilot program designed to harness AI to assess a patient's risk of developing breast cancer. The Genomics Risk Assessment for Cancer and Early ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

Virologist Beata Halassy says self-treatment worked and was a positive experience — but researchers warn that it is not ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...